A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
复制标题
DOI：
10.1016/j.vaccine.2021.05.102
复制
发表时间：
2021-12-03
期刊：
影响因子：
5.5
通讯作者：
Menozzi-Arnaud M
中科院分区：
文献类型：
--
作者：
Kristensen D;Giersing B;Hickling J;Kazi F;Scarna T;Kahn AL;Hsu V;Gandrup-Marino K;Menozzi-Arnaud M
As highlighted in the global Immunization Agenda 2030, advancements in products, services, and practices are required to achieve immunization coverage and equity goals and ensure that vaccines are accessible to all communities, especially the thirteen million ‘zero dose’children who are not receiving any vaccines via existing systems and strategies [1]. Innovative vaccine technologies and delivery devices can simplify logistics, increase the acceptability and safety of immunization, minimize missed opportunities, and facilitate outreach by overcoming ‘last mile’barriers. Although many initiatives have been undertaken to advance promising vaccine product innovations, most have been under-resourced; were not sufficiently evaluated to define a value proposition agreed upon by key stakeholders; lacked coordination and alignment of strategies and activities between donors, global agencies, and technology developers; and have not had the benefit of intentional market-shaping efforts to ensure that the innovations reach those who need them most. As described in an accompanying article, the result is that few have succeeded in being widely implemented and adopted in the low-resource settings where they could have the greatest impact [2]. The COVID-19 pandemic is now disrupting routine immunization and has further validated the need for new approaches to advance vaccine product innovations, including for COVID-19 vaccines.The Vaccine Innovation Prioritisation Strategy (VIPS) was formed in 2017 by Gavi, the Vaccine Alliance, and is a partnership between Gavi, the World Health Organization (WHO), Bill & Melinda Gates Foundation, United Nations Children’s Fund (UNICEF), and PATH. VIPS aims to pursue a common agenda of identifying and driving high priority vaccine product innovations forward to address the most important barriers to immunization and improve coverage and equity. VIPS has completed a first prioritization process by engaging with country and other stakeholders, developing common principles to evaluate and compare the benefits of innovations, establishing a platform and convening partners to agree upon the highest priority innovations, and communicating clear and aligned perspectives on the priorities to inform investment decisions. Although VIPS was formed prior to the pandemic, the relevance of the innovations to future COVID-19 vaccines as well as supplemental and outreach immunization activities to catch up millions of children who will miss essential services during the pandemic was considered during the final stage of the prioritization process.
